• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Rep. Kate Porter Confronts Pharma CEO: ‘You Refined Your Skills at Price Gouging’

Rep. Kate Porter Confronts Pharma CEO: ‘You Refined Your Skills at Price Gouging’

September 30, 2020
STEPHEN MOORE: Why Is Trump Funding The World Bank And The IMF?

STEPHEN MOORE: Why Is Trump Funding The World Bank And The IMF?

June 12, 2025
Trump Rejects $15M Offer From Paramount Over ’60 Minutes’ Lawsuit: Report

Trump Toots His Own Horn: ‘I could have been a flutist’

June 12, 2025
Trump Seeking Military Costumes for Parade

Trump Seeking Military Costumes for Parade

June 12, 2025
‘No Great Big Grand Final Bargain’: Brit Hume Says Deal With China Still ‘Has A Long Way To Go’

‘No Great Big Grand Final Bargain’: Brit Hume Says Deal With China Still ‘Has A Long Way To Go’

June 11, 2025
‘Who’s Gonna Do Your Manicure?’: Jessica Tarlov Yells As Watters Presses On Deportations

‘Who’s Gonna Do Your Manicure?’: Jessica Tarlov Yells As Watters Presses On Deportations

June 11, 2025
Big Tech Whistles Along While World Rides Trump-Musk Rollercoaster

Big Tech Whistles Along While World Rides Trump-Musk Rollercoaster

June 11, 2025
Democrat Rep Goes On Unhinged Rant About Her Own Lady Parts

Democrat Rep Goes On Unhinged Rant About Her Own Lady Parts

June 11, 2025
Air Force Loses Appetite For Shiny Fighter Jet With Huge Price Tag

Air Force Loses Appetite For Shiny Fighter Jet With Huge Price Tag

June 11, 2025
State Department Authorizes Middle East Evacuations As Iran Speculation Swirls

State Department Authorizes Middle East Evacuations As Iran Speculation Swirls

June 11, 2025
Maxine Waters Blames Trump For LA Violence She Previously Claimed Wasn’t Even Happening

Maxine Waters Blames Trump For LA Violence She Previously Claimed Wasn’t Even Happening

June 11, 2025
FBI Admits What Its Fmr Director Wouldn’t Say About Biden’s Afghanistan Withdrawal

FBI Admits What Its Fmr Director Wouldn’t Say About Biden’s Afghanistan Withdrawal

June 11, 2025
EXCLUSIVE: ‘Right Thing To Do’: Thune Goes To Mat For Medicaid Reforms In ‘Big, Beautiful’ Bill

EXCLUSIVE: ‘Right Thing To Do’: Thune Goes To Mat For Medicaid Reforms In ‘Big, Beautiful’ Bill

June 11, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Thursday, June 12, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home IJR

Rep. Kate Porter Confronts Pharma CEO: ‘You Refined Your Skills at Price Gouging’

by Alex Thomas
September 30, 2020
in IJR
240 12
10
Rep. Kate Porter Confronts Pharma CEO: ‘You Refined Your Skills at Price Gouging’
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

Freshman Congresswoman Katie Porter (D-Calif.) has made her name in Washington, D.C., with intense and successful lines of questioning during Congressional hearings and on Wednesday, Porter’s examination of a pharmaceutical CEO went viral.

Porter confronted former Celgene CEO Mark Ailes, specifically honing in on Celenge’s price hikes of revlimid, a drug used to treat cancer — the drug cost $215 per dose in 2005 and now costs $763, according to the medical news site STAT. Ailes eventually sold Celenge to Bristol-Myers Squibb.

The California congresswoman, wrote $13 million on a whiteboard, noting that was Ailes’ salary while CEO of Celenge. Porter then noted that roughly $2.1 of Ailes’ salary was a bonus for hitting “yearly-earning targets.”

She continued, “Any increase in the price of revlimid would also increase your bonus by increasing earnings. Isn’t that right, Mr. Ailes.”

Ailes responded, “If revenues increased and expenses did not, then earnings would be enhanced.”

Porter noted that “the Oversight Committee found that if you hadn’t increased the price of revlimid, then you wouldn’t have gotten your bonus.” Porter then wrote down another figure on her whiteboard and noted that Ailes received $500,000 because of the price hikes.

She added, “To recap here, the drug didn’t get any better, the cancer patients didn’t get any better. You just got better at making money. You just refined your skills at price gouging and to be clear, the taxpayers spent $3.3 billion on revlimid.”

Oh my god, Katie Porter. pic.twitter.com/tO6B7xCx3G

— Public Citizen (@Public_Citizen) September 30, 2020

Porter adds Ailes to the long list of CEOs that she has blasted during congressional hearings. She’s blasted the CEO of Equifax after their lawyers argued that a security breach didn’t harm anybody, and the CEO of JP Morgan Chase amid pay disparities in the company.

Porter holds a powerful seat on the House Oversight Committee that also includes freshmen Congresswomen Alexandria Ocasio-Cortez (D-N.Y.), Rashida Tlaib (D-Mich.), and Ayanna Pressley (D-Mass.).

Tags: Katie porter
Share196Tweet123
Alex Thomas

Alex Thomas

Alex is a Washington DC based contributor. He is from Delaware and holds a degree in English from Salisbury University. Find him on Twitter @AlexThomasDC

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th